30% Plunge for QuidelOrtho as Weak Flu Season Hits Q1 Revenue
summarizeSummary
QuidelOrtho Corp (QDEL) shares plummeted 30% after the company reported preliminary first-quarter 2026 revenue of $615-$620 million, significantly below Wall Street estimates of $671.8 million. This follows the 8-K and news reports from yesterday disclosing the preliminary figures. The company attributed the miss to a weaker respiratory illness season, with a 30% drop in U.S. influenza-like illness visits, alongside slower China distributor sales and delayed EMEA orders due to geopolitical tensions. The substantial stock decline indicates a severe market reaction to the revenue shortfall and the broader operational challenges. While the company anticipates negative free cash flow in the first half of 2026, it expects to turn positive for the full year and reiterated that the low end of its full-year guidance remains achievable. Investors will be watching for the official earnings report on May 5 for further details and outlook.
At the time of this announcement, QDEL was trading at $11.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $815.3M. The 52-week trading range was $11.61 to $38.99. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.